北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 期刊论文
学科主题: 临床医学
题名:
Phase III study of afatinib vs placebo as adjuvant therapy after chemo-radiotherapy (CRT) in primary unresected patients with locoregionally advanced (LA) head and neck squamous cell carcinoma (HNSCC) in Asia: LUX-Head & Neck 4 (LUX-H&N4)
作者: Hu, C. S.1; Chan, A.2; Gao, L.3; Ahn, M. -J.4; Cohen, E.5; Ang, M. -K.6; Cheng, Y.7; Hu, Q.8; Kim, S. -B.9; Li, P.10; Sun, Y.11; Fan, B.12; Cheng, G.13; Ehrnrooth, E.14; Wang, C. -H.15
刊名: ANNALS OF ONCOLOGY
发表日期: 2015-12-01
卷: suppl.9, 页:100-100
收录类别: SCI ; ISTP
文章类型: Meeting Abstract
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
语种: 英语
WOS记录号: WOS:000367158700338
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/65199
Appears in Collections:北京大学临床肿瘤学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Natl Canc Ctr, Dept Med Oncol, Singapore, Singapore
2.Tumor Hosp Jilin Prov, Div Thorac Oncol, Changchun, Peoples R China
3.Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea
4.Fudan Univ, Shanghai Canc Ctr, Shanghai 200433, Peoples R China
5.Chinese Univ Hong Kong, Sir YK Pao Ctr Canc, Hong Kong, Hong Kong, Peoples R China
6.Chinese Acad Med Sci, Canc Inst & Hosp, Beijing 100730, Peoples R China
7.Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
8.Univ Calif San Diego, Dept Med, Moores Canc Ctr, La Jolla, CA 92093 USA
9.Zhejiang Canc Hosp, Head & Neck Canc Ctr, Hangzhou, Zhejiang, Peoples R China
10.Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China
11.Peking Univ, Canc Hosp, Sch Oncol, Beijing 100871, Peoples R China
12.Boehringer Ingelheim China Investment Co Ltd, Med, Shanghai, Peoples R China
13.Boehringer Ingelheim China Investment Co Ltd, Biometr & Data Management, Shanghai, Peoples R China
14.Boehringer Ingelheim GmbH & Co KG, TA Oncol, Copenhagen, Denmark
15.Chang Gung Mem Hosp Keelung, Dept Canc Ctr, Taipei, Taiwan

Recommended Citation:
Hu, C. S.,Chan, A.,Gao, L.,et al. Phase III study of afatinib vs placebo as adjuvant therapy after chemo-radiotherapy (CRT) in primary unresected patients with locoregionally advanced (LA) head and neck squamous cell carcinoma (HNSCC) in Asia: LUX-Head & Neck 4 (LUX-H&N4)[J]. ANNALS OF ONCOLOGY,2015,suppl.9:100-100.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Hu, C. S.]'s Articles
[Chan, A.]'s Articles
[Gao, L.]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Hu, C. S.]‘s Articles
[Chan, A.]‘s Articles
[Gao, L.]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace